What is Levofloxacin Market?
Levofloxacin is a prescription drug available as an oral tablet, an oral solution, and an ocular solution (eye drop). It is also available in an intravenous (IV) form that can only be administered by a medical professional. Several bacterial infections are treated with levofloxacin. This medicine is a member of the quinolone antibiotics drug class. It acts by preventing bacterial development. Only bacterial illnesses are treated by this antibiotic. For viral infections, it is ineffective (such as common cold, and flu). Any antibiotic that is overused may stop working to treat subsequent illnesses. Growing geriatric populations helps to influence the market.
Highlights from Levofloxacin Market Study
|Unit||Value (USD Million)|
|Key Companies Profiled||Ortho McNeil Janssen Pharmaceuticals Inc (United States), Teva Pharmaceuticals (Israel), DKSH Holding (Switzerland), Dr. Reddy's Laboratories (India), Chemo Iberica, S.A. (Spain), UQUIFA (Spain), Zhejiang Langhua Pharmaceutical Co., Ltd (China), Hec Pharma Co., Ltd. (China) and Zhejiang Jingxin Pharmaceutical Co. Ltd. (China)|
The players in the Levofloxacin market focused on the acquisition to enhance their market presence. The companies are also planning strategic activities like partnerships, mergers, and new launches which will help them to sustain in the market and maintain their competitive edge. Ortho McNeil Janssen Pharmaceuticals Inc (United States), Teva Pharmaceuticals (Israel), DKSH Holding (Switzerland), Dr. Reddy's Laboratories (India), Chemo Iberica, S.A. (Spain), UQUIFA (Spain), Zhejiang Langhua Pharmaceutical Co., Ltd (China), Hec Pharma Co., Ltd. (China) and Zhejiang Jingxin Pharmaceutical Co. Ltd. (China) are some of the key players profiled in the study.
Levofloxacin Market Segmentation:
|Application / End User||Nausea or vomiting, Diarrhea, Headache and Others|
On the basis of geography, the market of Levofloxacin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Factors such as Increasing Incidences of Bacterial Infections such as Pneumonia & Urinary Tract Infections (UTI) and Broad Spectrum Efficacy
- Rising Geriatric Population
- Regulatory Guidelines on the Intake of Levofloxacin
- Growing Initiatives by The Government to Spread Awareness about Severe Infections can create Opportunities for the Market Growth
- Side Effects Associated with Levofloxacin such as Tendon Inflammation, Psychosis, and Seizures
Market Leaders & Development Strategies
On 21st February 2022, Binnopharm Group announced the signing of a deal that will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet (ciprofloxacin) and Levolet (levofloxacin) brands from Dr. Reddy's Laboratories. The portfolio contains a range of dosage forms, including tablets, infusion solutions, and ocular drops. The acquisition of Ciprolet and Levolet is a crucial step in strengthening our position in the antibiotics market, one of Binnopharm Group's major market areas.
According to the FDA-approved prescribing information, levofloxacin is pregnancy category C. This designation indicates that animal reproduction studies have shown adverse effects on the fetus and there are no adequate and well-controlled studies in humans, but the potential benefit to the mother may in some cases outweigh the risk to the fetus. The available data point to a low risk for the unborn child. Exposure to quinolones, including levofloxacin, during the first trimester, is not associated with an increased risk of stillbirths, premature births, birth defects, or low birth weight.
Key Target AudienceLevofloxacin Manufacturers, Levofloxacin Suppliers and Distributors, Regulatory Bodies, Potential Investors, New Entrants, Research and Development Institutes and Others